Lung Diseases

Boehringer Ingelheim has 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.

For information specific to Lung Cancer, please click here.

Collaborative Working Project

Collaborative Working Case Study: Papworth

Collaborative Working Project between Boehringer Ingelheim, Royal Papworth Hospital NHS Foundation Trust and East Suffolk and North Essex NHS Foundation Trust (ESNEFT) to develop and implement a shared care pathway for patients with interstitial lung disease.

NP-GB-107089 March 2026

Bronchiectasis

Bronchiectasis is a progressive inflammatory respiratory disease characterised by irreversible enlarged airways, which prevent proper mucus drainage.

Read more

Variation of management and treatment of ILD across England

Illustrating the variation of management and treatment of interstitial lung disease (ILD) across England.

Interstitial Lung Disease

Interstitial lung disease (ILD) refers to a group of over 200 chronic lung disorders involving inflammation and pulmonary fibrosis.